Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients
Aging · 2024-03-31 · 16 (6) · 5354-5369
DOI: 10.18632/aging.205652 ↗At a glance
Systematische Übersicht in Aging, published online on 2024-03-11. Written by Yean Yu and 4 co-authors. Institution: Department of Nephrology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China. Major MEDLINE topics: Cachexia, Immune Checkpoint Inhibitors, Neoplasms. Cited 16 times so far (Crossref); 49 references. The full text is freely available in PubMed Central.
Topics: Onkologische Pflege
Abstract (original language)
OBJECTIVE: Cachexia, a multifactorial syndrome, is frequently noticed in cancer patients. A recent study has shown inconsistent findings about the relationship between cachexia and the efficiency of immune checkpoint inhibitors (ICIs). To analyze this disparity, we did a meta-analysis. METHODS: From the beginning of each database to July 2023, literature describing the association between cachexia and prognosis of ICI-treated patients with solid malignancies was systematically searched in three online databases. Estimates were pooled, and 95% confidence intervals (CIs) were generated. RESULTS: We analyzed a total of 12 articles, which included data from 1407 patients. The combined results of our analysis showed that cancer patients with cachexia had significantly worse overall survival (HR = 1.88, 95% CI: 1.59-2.22, p < 0.001), progression-free survival (HR = 1.84, 95% CI: 1.59-2.12, p < 0.001), and time to treatment failure (HR = 2.15, 95% CI: 1.32-3.50, p = 0.002). These findings were consistent in both univariate and multivariate analyses. Additionally, while not statistically significant, we observed a trend towards a lower objective response rate in cancer patients with cachexia compared to those without cachexia (OR = 0.59, 95% CI: 0.32-1.09, p = 0.093). CONCLUSION: Poor survival in cachexia patients suggests a negative relationship between cachexia and ICI efficacy. In clinical practice, the existence of cachexia should be estimated to choose individuals who may benefit from ICIs.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Nephrology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China.
- Department of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China.
- Department of Abdominal and Pelvic Medical Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
- Department of Critical Care Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
- Department of Critical Care Medicine, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China.
Cite
APA
Yu, Y., Yan, L., Huang, T., Wu, Z., & Liu, J. (2024). Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients. Aging, 16(6), 5354-5369. https://doi.org/10.18632/aging.205652
Vancouver
Yu Y, Yan L, Huang T, Wu Z, Liu J. Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients. Aging. 2024;16(6):5354-5369. doi:10.18632/aging.205652
BibTeX
@article{Yu2024,
author = {Yu, Yean and Yan, Li and Huang, Tianhui and Wu, Zhenfu and Liu, Juan},
title = {Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients},
journal = {Aging},
year = {2024},
volume = {16},
number = {6},
pages = {5354--5369},
doi = {10.18632/aging.205652}
}
EUVIMED